Revisiting Beta-Blocker Therapy in Heart Failure with Preserved Ejection Fraction
<p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a cu...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Published: |
2023
|
| Subjects: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | <p dir="ltr">Heart failure with preserved ejection fraction (HFpEF) is a heterogenous disorder and tends to be predominant in elderly, female, and obese patients. HFpEF has been classified using various cut-offs of left ventricular ejection fraction in the published studies with a current cut-off of ≥50%. The evidence of beta-blocker therapy in HFpEF patients showed conflicting findings with variably reported efficacy. This review aims to examine the published studies on the use of beta blockers for the treatment of patients with HFpEF.</p><h3>Other Information</h3><p dir="ltr">Published in: Current Problems in Cardiology<br>License: <a href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1016/j.cpcardiol.2023.102015" target="_blank">https://dx.doi.org/10.1016/j.cpcardiol.2023.102015</a></p> |
|---|